

# **Diagnostic and Prognostic Value of Global Longitudinal Strain in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis**

1 **Yujiao Shi<sup>1</sup>, Wang Qing<sup>1</sup>, Chunqiu Liu<sup>1</sup>, Xiong Shuang<sup>1</sup>, Chenguang Yang<sup>1</sup>,**

2 **Wenbo Qiao<sup>1</sup>, Guoju Dong<sup>1,2\*</sup>, Jiangang Liu<sup>2\*</sup>**

3

4 <sup>1</sup>Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of  
5 Traditional Chinese Medicine, Beijing, China

6 <sup>2</sup>National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital,  
7 Chinese Academy of Traditional Chinese Medicine, Beijing, China

8

9 \* Corresponding Author

10 E-mail: Guoju Dong. e-mail: 13691393589@163.com (GD); liujiangang2002@sina.com  
11 (JL)

12

13

14

15

16

17

18

19

20

21

22

23

24

25 **Abstract**

26 **Objective:** Heart failure with preserved ejection fraction (HFpEF), an increasing public  
27 health concern, is increasing in prevalence and is associated with an elevated risk of  
28 hospitalization and mortality. Currently, data on the clinical application value of left  
29 ventricular global longitudinal strain (LV GLS) in HFpEF are contradictory. Therefore,  
30 we performed the following meta-analysis to appraise the diagnostic and prognostic value  
31 of LV GLS in HFpEF.

32 **Methods:** PubMed, Medline, Scopus, and Web of Science were retrieved exhaustively  
33 from their inception until December 20, 2022, to obtain literature assessing the diagnostic  
34 and prognostic value of LV GLS in HFpEF.

35 **Results:** Forty-one studies (including 14,543 patients) published from 2008 to 2022 were  
36 included. The results of the meta-analysis were as follows: First, the LV GLS values in  
37 HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI  
38 (0.94, 1.47),  $p < 0.00001$ ,  $I^2 = 85\%$ ;  $P < 0.00001$ ), but substantially higher than in HErEF  
39 patients (SMD: -2.03; 95% CI (-2.23, -1.72),  $p < 0.00001$ ,  $I^2 = 92\%$ ;  $P < 0.00001$ ). Second,  
40 the pooled diagnostic parameters of LV GLS for HFpEF were as follows: sensitivity,  
41 0.77 (95% CI: 0.71–0.82); specificity, 0.66 (95% CI: 0.58–0.74); DOR, 7.53 (95% CI:  
42 3.19–17.74); AUC for the SROC, 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS  
43 values were correlated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-  
44 1.25;  $p = 0.000$ ,  $I^2 = 84\%$ ;  $P = 0.031$ ) in HFpEF patients.

45 **Conclusions:** LV GLS is impaired in HFpEF patients despite a normal left ventricular  
46 ejection fraction, indicating the existence of mild LV contractile dysfunction. Moreover,  
47 LV GLS might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause

48 death in HFpEF patients.

49 **Keywords:** Global longitudinal strain; Heart failure with preserved ejection fraction;

50 Diagnosis; Prognosis; Meta-analysis

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

## 71 **1 Introduction**

72 Heart failure (HF) with preserved ejection fraction (HFpEF), a complex and  
73 heterogeneous ailment, is a multi-organ disorder caused by an aging populace and  
74 comorbidities such as obesity, hypertension, diabetes, and chronic renal insufficiency[1].  
75 HFpEF, comprising approximately half of the population of HF, is increasing in  
76 prevalence and is associated with an elevated risk of hospitalization and mortality[2,3].  
77 Nevertheless, the clinical manifestations of HFpEF are atypical, and the pathogenic  
78 mechanism remains poorly understood, limiting clinical diagnosis and therapeutic  
79 options[4,5]. Accordingly, early and accurate diagnosis of HFpEF and determination of  
80 prognosis can contribute to implementing appropriate interventions to slow or halt  
81 disease progression and improve long-term consequences.

82 Despite the fact that patients with HFpEF have a left ventricular (LV) ejection  
83 fraction (LVEF) of greater than or equal to 50%, cardiac contractile performance may  
84 still be damaged, especially in individuals with severe concentric cardiac hypertrophy or  
85 a small LV cavity[6]. LVEF, a measure of overall cardiac systolic function derived from  
86 two-dimensional echocardiographic images, may be limited by altered cardiac geometry,  
87 boundary tracking difficulties, and other factors[7,8]. Compared with LVEF  
88 measurement, myocardial strain, which represents the percentage deformation of the  
89 myocardium in three directions (longitudinal, circumferential, and radial) during the  
90 cardiac cycle, is an emerging metric allowing more precise quantification of global and  
91 regional myocardial contractile function[9]. LV global longitudinal strain (LV GLS),  
92 which can be measured by speckle-tracking echocardiography (STE) or feature-tracking  
93 cardiovascular magnetic resonance (FT-CMR), is a commonly used myocardial strain

94 parameter in cardiovascular diseases[10]. In recent years, multiple clinical trials have  
95 analyzed the diagnostic or prognostic significance of LV GLS in HFpEF, but they  
96 provided inconsistent results. In this situation, we implemented a meta-analysis to  
97 estimate the diagnostic and prognostic value of LV GLS in HFpEF.

98

## 99 **2 Materials and methods**

### 100 **2.1 Literature Search Strategy**

101 This systematic review and meta-analysis was performed depending on the principles  
102 of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020  
103 statement (PRISMA)[11]. Two investigators (Shi and Wang) systematically performed  
104 documentary searches in four electronic databases (PubMed, Medline, Scopus, and Web  
105 of Science). English-language literature published from the inception of each database  
106 until December 20, 2022, was searched. Terms related to "Heart Failure, Diastolic",  
107 "Heart Failure with Preserved Ejection Fraction", "Heart Failure with Normal Ejection  
108 Fraction", "Diastolic Dysfunction", " Preserved Ejection Fraction", "Global Longitudinal  
109 Strain", and "GLS" were utilized following the rules of each database. For PubMed, the  
110 following search was performed: (((((Heart Failure, Diastolic[MeSH Terms]) OR (Heart  
111 Failure with Preserved Ejection Fraction[Title/Abstract])) OR (Heart Failure with Normal  
112 Ejection Fraction[Title/Abstract])) OR (Diastolic Dysfunction[Title/Abstract])) OR  
113 (Preserved Ejection Fraction[Title/Abstract])) AND ((Global Longitudinal  
114 Strain[Title/Abstract]) OR (GLS[Title/Abstract]))

### 115 **2.2 Literature Inclusion and Exclusion Criteria**

116 The inclusion criteria for this study were as follows: (i) diagnostic criteria: Fulfilment  
117 of diagnostic criteria for HF, patients with HFpEF had an LVEF $\geq$ 45%, while HFrEF  
118 patients had an LVEF  $\leq$ 40%[12,13]; (ii) study design: observational studies like case-  
119 control studies, prospective and retrospective cohort studies; (ii) endpoints: difference in  
120 LV GLS values between HFpEF patients and control groups (health controls or HFrEF  
121 patients), as well as the connection between LV GLS and diagnosis or adverse endpoints  
122 of HFpEF. The exclusion criteria for this study were as follows: (i) irrelevant or  
123 duplicated studies; (ii) the papers were case reports, reviews, letters, commentaries,  
124 editorials, or non-human studies; and (iii) the articles lacked full text or sufficient crude  
125 data.

### 126 **2.3 Literature Quality Evaluation and Data Extraction**

127 The quality estimation of the enrolled studies was evaluated by two independent  
128 reviewers (Xiong and Liu) using the Newcastle–Ottawa Quality Assessment Scale (NOS)  
129 system, a "star-based" grading system comprised of three parts (selection, comparability,  
130 and outcomes). A total NOS score ranged from 0 to 9, and studies achieving a score of 6  
131 or above were considered high quality (Supplementary Table 1).

132 The required data from the included research was extracted and tabulated in  
133 specifically constructed Microsoft Excel spreadsheets for analysis. The extracted contents  
134 were as follows: (i) publication details: last name of the first author, year of publication,  
135 and the country setting; (ii) demographic characteristics: sample size, proportions of  
136 males, and mean age; (iii) study details: study design, LV GLS measurement method,  
137 data available to calculate the standardized mean difference (SMD) of LV GLS values  
138 between HFpEF patients and control groups (sample size, mean of LV GLS values and

139 standard deviation), data related to diagnostic meta-analysis (LV GLS cut-off, area under  
140 the curve (AUC), sensitivity (SEN), specificity (SPE), true positive (TP), false positive  
141 (FP), false negative (FN), true negative (TN)), and data associated with prognostic meta-  
142 analysis (variables adjusted, follow-up duration, endpoints (HF hospitalization,  
143 cardiovascular (CV) hospitalization, CV death, and All-cause death), hazard ratios (HRs)  
144 and 95% confidence intervals (CIs)); and (iv) NOS quality scores. Two independent  
145 researchers (Yang and Qiao) conducted data extraction, and disagreements were resolved  
146 by mutual coordination or third-party adjudication (Dong and Liu).

#### 147 **2.4 Statistical Analysis**

148 Meta-Disc (Version 14.0) was used to analyze the diagnostic value of LV GLS in  
149 HFpEF. The pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio  
150 (NLR), diagnostic odds ratio (DOR), and AUC for the summary receiver operating  
151 characteristic curves (SROC) were used to characterize the diagnostic performance.  
152 Review Manager (Version 5.4) was used to analyze the difference in LV GLS values  
153 between HFpEF patients and control groups. SMD and 95% CIs expressed the pooled  
154 effect sizes. STATA (Version 16.0) was used to assess the association between LV GLS  
155 and adverse outcomes of HFpEF. HRs and 95% CIs represented the pooled effect sizes.  
156 The heterogeneity among the included studies was appraised by the Cochran Q statistics  
157 (chi-square test) and quantified with the I<sup>2</sup> statistic. The fixed-effect model was  
158 employed when the Q test (I<sup>2</sup><50%, p>0.05) revealed no significant heterogeneity across  
159 studies. When the Q test (I<sup>2</sup>≥50% or p<0.05) found prominent heterogeneity among  
160 studies, the random-effect model was utilized, followed by a Galbraith plot to explore the  
161 source of heterogeneity. Publication bias was evaluated using Deeks' funnel plot, Funnel

162 plot, and Egger's test. Sensitivity analysis was employed to assess the impact of single  
163 research on the overall estimate by omitting one study each time.  $P < 0.05$  was considered  
164 to be statistically significant.

165

## 166 **3 Results**

### 167 **3.1 Literature Search Results**

168 A flowchart of the database search and text screening procedure is demonstrated in  
169 Fig 1. 2,492 publications were retrieved through database searching, consisting of 372  
170 from PubMed, 624 from Medline, 559 from Scopus, and 937 from Web of Science. After  
171 excluding 874 duplicates, we screened the titles and abstracts of 1,618 papers. 1,524  
172 articles were removed following the inclusion and exclusion criteria. Finally, among the  
173 remaining 94 studies, two independent researchers (Shi and Wang) read the full text and  
174 excluded 53 records due to repetitive research, irrelevant results, and insufficient data.  
175 Overall, 41 articles in total were enrolled in the meta-analysis.

### 176 **3.2 Characteristics of Included Studies**

177 Forty-one studies [14-53] published from 2008 to 2022 were investigated, including  
178 27 case-control studies, 12 prospective cohort studies, and 2 retrospective cohort studies.  
179 Table 1 shows the baseline features of the selected research. A total of 14,543 patients  
180 (10,193 HFpEF patients, 6,931 males, mean age of 67.66 years) were involved. Thirty-  
181 two studies detected LV GLS using STE, and the other 9 utilizing FT-CMR. Thirty-eight  
182 studies reported mean LV GLS values in HFpEF patients (-8.2% - -20.8%), whereas the



183 remaining 3 informed the median values (-15.3% - -20%). Concerning endpoint events,  
184 27 studies evaluated the differences in LV GLS values between HFpEF patients and  
185 healthy controls (21 research) or HFrEF patients (16 research), and 26 studies assessed  
186 the diagnostic (6 trials) and prognostic (18 trials) significance of LV GLS in HFpEF. The  
187 NOS scores of included research varied from 6 to 9, indicating that the methodological  
188 quality was generally reliable (**S1 Appendix**).

### 189 **3.3 Differences in LV GLS Values Between HFpEF Patients and Control Groups**

190 Twenty-one studies[14–34] explored the differences in LV GLS values between  
191 HFpEF patients (n=1431) and healthy controls (n=864), with a mean LV GLS of -  
192 16.07%±3.32% vs. -19.54%± 2.57% (Fig 2A). Moreover, 16 studies[14–18,21,26,30,33–  
193 40] examined discrepancies in LV GLS values between HFpEF patients (n=2,234) and  
194 HFrEF patients (n=3,355), with an average LV GLS of -16.42%±3.56% vs. -9.3%±3.48%  
195 (Fig 2B). Meta-analysis using a random-effect model revealed that the LV GLS values in  
196 HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI  
197 (0.94, 1.47), p<0.00001, I<sup>2</sup>=85%; P<0.00001) (Fig 2C), but substantially higher than in  
198 HErEF patients (SMD: -2.03; 95% CI (-2.23, -1.72), p<0.00001, I<sup>2</sup>=92%; P<0.00001)  
199 (Fig 2D). According to the Galbraith radial plots, the research by (Fang et al., Wang et  
200 al., Sanchis et al.) and (Maffeis et al., Carluccio et al., and Yip et al.) were sources of  
201 heterogeneity for the above two comparison groups, respectively ( S2 Appendix. 1A,  
202 2A).

203 The associated Funnel plots were asymmetrical (S2 Appendix. 1B, 2B) and the p-values  
204 of Egger's test were 0.2 and 0.41 (S2 Appendix. 1C, 2C), indicating a potential  
205 publication bias among included studies. The sensitivity analyses removing one research

206 each time indicated that none of the individual trials substantially impacted the pooled  
207 estimates (S2 Appendix. 1D, 2D). Overall, the results of this study were relatively  
208 constant.

### 209 **3.4 Diagnostic Value of LVGLS in HFpEF**

210 Six studies[20,23,27,31–33] estimated the diagnostic usefulness of LV GLS values in  
211 HFpEF compared with healthy controls, with LV GLS cut-off values ranging from -16%  
212 to -24.1 and AUC from 0.68 to 0.98 (Table 2). Five trails provided complete data for  
213 diagnostic meta-analysis (SEN, SPN, TP, FP, FN, and TN). The SROC curve revealed no  
214 typical "shoulder-arm" pattern, while the Spearman correlation coefficient between the  
215 logarithm of sensitivity and the logarithm of (1-specificity) was -0.1,  $P=0.873$ , suggesting  
216 no threshold effect in the meta-analysis. Summary assessments of the diagnostic  
217 performance of LV GLS in HFpEF were as follows: SEN was 0.77 (95% CI: 0.71–0.82)  
218 (Fig 3A); SPE was 0.66 (95% CI: 0.58–0.74) (Fig 3B); PLR was 2.17 (95% CI: 1.36–  
219 3.47) (Fig 3C); NLR was 0.35 (95% CI: 0.21–0.59) (Fig 3D); DOR was 7.53 (95% CI:  
220 3.19–17.74) (Fig 3E); AUC for the SROC was 0.81 (95% CI: 0.79–0.87) (Fig 3F). The p-  
221 value of Deeks' test (0.18) was greater than 0.05, suggesting no significant publication  
222 bias. (S2 Appendix. 3).

### 223 **3.5 Prognostic Value of LV GLS in HFpEF Patients**

224 Eighteen studies[6,28,37,40–53] examined the connection between LV GLS values as  
225 a continuous variable and adverse outcomes in HFpEF patients. The duration of follow-  
226 up varied from 4 to 144 months. In 9 studies, variables such as age, sex, race, history of  
227 CV disease, medication history, laboratory tests, and others that might affect the

228 association between LV GLS and research outcomes were adjusted (Table 3). Meta-  
229 analyzes with random-effects models showed that the low LV GLS values in HFpEF  
230 patients were associated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-  
231 1.25;  $p=0.000$ ,  $I^2=84\%$ ;  $P = 0.031$ )[29,42,44,47,49,51] (Fig 4A), but not with the  
232 composite outcomes (all-cause death and HF hospitalization (HR: 1.03; 95% CI: 0.95-  
233 1.11;  $p=0.000$ ,  $I^2= 83\%$ ;  $P = 0.51$ )[29,45–48,51,52] (Fig 4B) or CV death and HF  
234 hospitalization (HR: 1.04; 95% CI: 0.94-1.14;  $p=0.000$ ,  $I^2= 81\%$ ;  $P = 0.49$ ))  
235 [6,28,37,41,43] (Fig 4C)). Additionally, three studies by Xu et al., Freed et al., and  
236 Kosmala et al. reported no association between low LV GLS values in HFpEF patients  
237 and the composite outcome of all-cause death and CV hospitalization [40,50,53]. The  
238 result for all-cause death showed substantial heterogeneity. The Galbraith radial plot  
239 suggested that the studies by Romano2020 et al. and Buggy2017 et al. may be the  
240 source of heterogeneity (S2 Appendix. 4A). the associated Funnel plot was asymmetric  
241 (S2 Appendix. 4B) and the p-value of Egger's test was 0.67 (S2 Appendix. 4C),  
242 suggesting a possible publication bias across included studies. The sensitivity analysis  
243 indicated that none of the studies significantly affected the pooled estimates (S2  
244 Appendix. 4D).

245

#### 246 **4 Discussion**

247 Current European Society of Cardiology guidelines graded HF based on LVEF into  
248 reduced (LVEF $\leq$ 40%), mildly reduced (LVEF 41-49%), and preserved (LVEF $\geq$ 50%)  
249 three subtypes[13]. HFpEF, which accounts for about half of all HF, is evolving as an  
250 increasingly severe public health concern[2]. Presently, HFpEF is diagnosed depending

251 on representative symptoms and/or signs of HF (breathlessness, fatigue, edema, and  
252 others), an LVEF of more than 50%, objective evidence of cardiac structural or  
253 functional abnormalities, and a growing level of BNP or NT pro-BNP[5]. However, most  
254 sufferers lack specific clinical manifestations in the initial stages and are usually not  
255 detected until the impairment of cardiac structure and function develops [54]. It is  
256 essential to explore effective metrics for identifying high-risk individuals, early  
257 diagnosis, prognosis assessment, and treatment monitoring.

258 During cardiac systole, the obliquely and oppositely oriented subendocardial and  
259 epicardial myofibers produce apical counter-clockwise torsion and basal clockwise  
260 torsion, causing the LV to shorten in the longitudinal and circumferential planes while  
261 thickening in the radial plane[55]. Cardiac strain assesses the change in length of the  
262 myocardium in three planes (longitudinal and circumferential (expressed by a negative  
263 value), radial (represented by a positive value) relative to the initial length during the  
264 cardiac cycle. It can be calculated using the following formula: strain (epsilon) =  $L - L_0 / L_0$  (where  $L_0$  is the baseline length of the myocardium, and  $L$  is the length after  
265 deformation)[7]. LV GLS, a sensitive and objective diagnostic indicator in cardiac strain  
266 imaging, can detect LV mild contractile dysfunction before changes in LVEF[8]. It is  
267 currently used as an auxiliary parameter for diagnosis and prognostic assessment in  
268 cardio-oncology[56] and is being expanded to other fields such as cardiac  
269 amyloidosis[57], cardiomyopathies[58], valvular heart diseases[59], pulmonary  
270 hypertension[60], and HF[58]. Although numerous studies have confirmed the presence  
271 of abnormal LV GLS in HFpEF patients and the Heart Failure Association consensus has  
272 unanimously recommended impaired V GLS as an ancillary criterion for the diagnosis of  
273

274 HFpEF[54], there is controversy about whether LV GLS has independent diagnostic and  
275 prognostic value for HFpEF. We consequently performed this meta-analysis to assess the  
276 diagnostic and prognostic value of LV GLS in HFpEF.

277 The results of the current meta-analysis illustrated a significant link between LV GLS  
278 and the diagnosis and prognosis of HFpEF. First, the LV GLS values in HFpEF patients  
279 were significantly lower than in healthy individuals, but substantially higher than in  
280 HErEF patients, confirming the presence of mild LV systolic dysfunction in HFpEF  
281 patients. The longitudinal systolic function of LV is determined by the endocardium,  
282 which is highly susceptible to the detrimental impacts of ischemia or hypertrophy[61,62].  
283 Multiple comorbidities in HFpEF patients may promote microvascular malfunction and  
284 muscle fibrosis[63], reducing LV longitudinal systolic function and ultimately leading to  
285 LV GLS impairment. Second, LV GLS has excellent auxiliary diagnostic value for  
286 HFpEF, with with an AUC of 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS values  
287 in HFpEF patients were correlated with a higher risk of all-cause death, indicating that  
288 LV GLS is a powerful independent predictor of all-cause mortality in HFpEF patients.

289 This meta-analysis involved a relatively comprehensive literature search, and the  
290 included studies were of excellent quality according to the NOS score. Nonetheless, some  
291 limitations must be considered: First, the heterogeneity of the included studies was high,  
292 with probable causes including the detection method of LV GLS, the diagnostic criteria  
293 of HF, and the study design. Second, in the diagnostic meta-analysis, the diagnostic cut-  
294 off values of LV GLS were not consistent, which might be related to factors like the  
295 detection technique. Third, in the prognostic meta-analysis, the follow-up periods were  
296 inconsistent, and the number of studies in which effect sizes could be combined for the

297 same endpoint was low, limiting the ability to draw significant conclusions. As a result,  
298 our meta-analysis is exploratory, and further high-quality original research is needed to  
299 support the findings of this study.

300

## 301 **5 Conclusion**

302 LV GLS is impaired in HFpEF patients despite a normal left ventricular ejection  
303 fraction, indicating the existence of mild LV contractile dysfunction. Moreover, LV GLS  
304 might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause death in  
305 HFpEF patients.

306

## 307 **6 Supporting information**

308 **S1 Appendix. NOS score of the included studies (PDF)**

309 **S2 Appendix. Heterogeneity, publication bias, and sensitivity analysis of relevant**  
310 **meta-analyses (PDF)**

311 **S3 Appendix. PRISMA checklist (PDF)**

312

## 313 **7 Acknowledgments**

314 The authors would like to express their gratitude to Professor W. Szymański for his  
315 valuable help in the process of retrieving relevant literature.

316

317

318 **8 Author Contributions**

319 **Conceptualization:** Yujiao Shi, Guoju Dong, Jiangang Liu

320 **Data curation:** Yujiao Shi, Wang Qing

321 **Formal analysis:** Wang Qing, Chunqiu Liu, Xiong Shuang

322 **Investigation:** Chenguang Yang, Wenbo Qiao

323 **Methodology:** Yujiao Shi, Guoju Dong, Jiangang Liu

324 **Project administration:** Wang Qing, Chunqiu Liu, Xiong Shuang

325 **Supervision:** Guoju Dong, Jiangang Liu

326 **Visualization:** Yujiao Shi, Chunqiu Liu

327 **Writing – original draft:** Guoju Dong, Jiangang Liu

328 **Writing – review & editing:** Yujiao Shi, Guoju Dong, Jiangang Liu

329

330 **9 Data availability statement**

331 All relevant data are within the paper.

332

333 **10 Funding**

334 This study was supported by grants from the National Natural Science Foundation of

335 China (8207153216) and the Major Innovation Project of the China Academy of

336 Traditional Chinese Medicine (CI2021A00903).

337

338

339

## 340 Reference

- 341 1. Borlaug BA. Evaluation and management of heart failure with preserved ejection  
342 fraction. *Nature Reviews Cardiology* (2020) 17:559–73. doi: 10.1038/s41569-  
343 020-0363-2
- 344 2. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R,  
345 Chirinos JA, Collins S, Deo RC, Gladwin MT, et al. Research Priorities for Heart  
346 Failure With Preserved Ejection Fraction. *Circulation* (2020) 141:1001–26. doi:  
347 10.1161/circulationaha.119.041886
- 348 3. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with  
349 preserved ejection fraction. *Nature Reviews Cardiology* (2017) 14:591–602. doi:  
350 10.1038/nrcardio.2017.65
- 351 4. Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection  
352 Fraction: Mechanisms and Treatment Strategies. *Annual Review of Medicine*  
353 (2022) 73:321–37. doi: 10.1146/annurev-med-042220-022745
- 354 5. Nagueh SF. Heart Failure with Preserved Ejection Fraction: Insights into  
355 Diagnosis and Pathophysiology. *Cardiovascular Research* (2021) 117:999–1014.  
356 doi: 10.1093/cvr/cvaa228
- 357 6. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer  
358 MA, Solomon SD. Prognostic Importance of Impaired Systolic Function in Heart  
359 Failure With Preserved Ejection Fraction and the Impact of Spironolactone.  
360 *Circulation* (2015) 132:402–14. doi: 10.1161/CIRCULATIONAHA.115.015884
- 361 7. Potter E, Marwick TH. Assessment of Left Ventricular Function by  
362 Echocardiography. *JACC: Cardiovascular Imaging* (2018) 11:260–74. doi:  
363 10.1016/j.jcmg.2017.11.017
- 364 8. Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic  
365 dysfunction when left ventricular ejection fraction is normal. *European Journal*  
366 *of Heart Failure* (2018) 20:1636–8. doi: 10.1002/ejhf.1326
- 367 9. Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function:  
368 from ejection fraction to strain analysis. *European Heart Journal* (2021) 42:789–  
369 97. doi: 10.1093/eurheartj/ehaa587
- 370 10. Amzulescu MS, De Craene M, Langet H, Pasquet A, Vancraeynest D, Pouleur  
371 AC, Vanoverschelde JL, Gerber BL. Myocardial strain imaging: review of  
372 general principles, validation, and sources of discrepancies. *European Heart*  
373 *Journal - Cardiovascular Imaging* (2019) 20:605–19. doi: 10.1093/ehjci/jez041
- 374 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,  
375 Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020  
376 statement: an Updated Guideline for Reporting Systematic Reviews. *British*  
377 *Medical Journal* (2021) 372:n71. doi: 10.1136/bmj.n71
- 378 12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez  
379 F, Packer M, Pfeffer MA, Pieske B, et al. Angiotensin–Neprilysin Inhibition in  
380 Heart Failure with Preserved Ejection Fraction. *New England Journal of*  
381 *Medicine* (2019) 381:1609–20. doi: 10.1056/nejmoa1908655
- 382 13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri  
383 H, Butler J, Čelutkienė J, Chioncel O, et al. 2021 ESC Guidelines for the  
384 Diagnosis and Treatment of Acute and Chronic Heart Failure. *European Heart*  
385 *Journal* (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368



- 386 14. Bekfani T, Hamadanchi A, Ijuin S, Bekhite M, Nisser J, Derlien S, Westphal J,  
387 Bogoviku J, Morris DA, Fudim M, et al. Relation of left atrial function with  
388 exercise capacity and muscle endurance in patients with heart failure. *ESC Heart*  
389 *Failure* (2021) 8:4528–38. doi: 10.1002/ehf2.13656
- 390 15. Blum M, Hashemi D, Motzkus LA, Neye M, Dordevic A, Zieschang V, Zamani  
391 SM, Lapinskas T, Runte K, Kelm M, et al. Variability of Myocardial Strain  
392 During Isometric Exercise in Subjects With and Without Heart Failure. *Frontiers*  
393 *in Cardiovascular Medicine* (2020) 7:111. doi: 10.3389/fcvm.2020.00111
- 394 16. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally F, Leong  
395 KTG, Ong HY, Ng TP, et al. Right ventricular dysfunction in left-sided heart  
396 failure with preserved versus reduced ejection fraction. *European Journal of*  
397 *Heart Failure* (2017) 19:1664–71. doi: 10.1002/ejhf.873
- 398 17. Bshiebish HAH, Al-Musawi AH, Khudeir SA. Role of global longitudinal strain  
399 in assessment of left ventricular systolic function in patients with heart failure  
400 with preserved ejection fraction. *Journal of the Saudi Heart Association* (2019)  
401 31:100–5. doi: 10.1016/j.jsha.2018.12.002
- 402 18. Carluccio E, Biagioli P, Alunni G, Murrone A, Leonelli V, Pantano P, Biscottini  
403 E, Paulus WJ, Ambrosio G. Advantages of deformation indices over systolic  
404 velocities in assessment of longitudinal systolic function in patients with heart  
405 failure and normal ejection fraction. *European Journal of Heart Failure* (2011)  
406 13:292-02. doi: 10.1093/eurjhf/hfq203
- 407 19. Carluccio E, Biagioli P, Zuchi C, Bardelli G, Murrone A, Lauciello R, D’Addario  
408 S, Mengoni A, Alunni G, Ambrosio G. Fibrosis assessment by integrated  
409 backscatter and its relationship with longitudinal deformation and diastolic  
410 function in heart failure with preserved ejection fraction. *The International*  
411 *Journal of Cardiovascular Imaging* (2016) 32:1071–80. doi: 10.1007/s10554-  
412 016-0881-5
- 413 20. Fang S, Zhang Z, Wang Y, Jiang F, Yang K, He F, Zhang C. Predictive value of  
414 left ventricular myocardial strain by four-dimensional speckle tracking  
415 echocardiography combined with red cell distribution width in heart failure with  
416 preserved ejection fraction. *Echocardiography* (2019) 36:1074–83. doi:  
417 10.1111/echo.14373
- 418 21. Hashemi D, Motzkus L, Blum M, Kraft R, Tanacli R, Tahirovic E, Doebelin P,  
419 Zieschang V, Zamani SM, Kelm M, et al. Myocardial deformation assessed  
420 among heart failure entities by cardiovascular magnetic resonance imaging. *ESC*  
421 *Heart Failure* (2021) 8:890–7. doi: 10.1002/ehf2.13193
- 422 22. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K, Omori T, Dohi K,  
423 Ito M, Sakuma H. Cardiovascular magnetic resonance feature tracking for  
424 characterization of patients with heart failure with preserved ejection fraction:  
425 correlation of global longitudinal strain with invasive diastolic functional indices.  
426 *Journal of Cardiovascular Magnetic Resonance* (2020) 22:42. doi:  
427 10.1186/s12968-020-00636-w
- 428 23. Kim HY, Park S-J, Lee S-C, Chang SY, Kim E-K, Chang S-A, Choi J-O, Park  
429 SW, Kim S-M, Choe YH, et al. Comparison of global and regional myocardial  
430 strains in patients with heart failure with a preserved ejection fraction vs  
431 hypertension vs age-matched control. *Cardiovascular Ultrasound* (2020) 18:44.

- 432 doi: 10.1186/s12947-020-00223-0
- 433 24. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile
- 434 MR, Voors AA, Lefkowitz MP, Packer M, et al. Impaired Systolic Function by
- 435 Strain Imaging in Heart Failure With Preserved Ejection Fraction. *Journal of the*
- 436 *American College of Cardiology* (2014) 63:447–56. doi:
- 437 10.1016/j.jacc.2013.09.052
- 438 25. Löffler AI, Pan JA, Balfour PC, Shaw PW, Yang Y, Nasir M, Auger DA, Epstein
- 439 FH, Kramer CM, Gan L-M, et al. Frequency of Coronary Microvascular
- 440 Dysfunction and Diffuse Myocardial Fibrosis (Measured by Cardiovascular
- 441 Magnetic Resonance) in Patients With Heart Failure and Preserved Left
- 442 Ventricular Ejection Fraction. *The American Journal of Cardiology* (2019)
- 443 124:1584–9. doi: 10.1016/j.amjcard.2019.08.011
- 444 26. Luo X-X, Fang F, Lee AP-W, Sun J-P, Li S, Zhang Z-H, Sanderson JE, Kwong
- 445 JSW, Zhang Q, Wang J, et al. What can three-dimensional speckle-tracking
- 446 echocardiography contribute to evaluate global left ventricular systolic
- 447 performance in patients with heart failure? *International Journal of Cardiology*
- 448 (2014) 172:132–7. doi: 10.1016/j.ijcard.2013.12.314
- 449 27. Mordi IR, Singh S, Rudd A, Srinivasan J, Frenneaux M, Tzemos N, Dawson DK.
- 450 Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation
- 451 Differentiates Among Heart Failure With Preserved Ejection Fraction Patients,
- 452 Hypertensive Patients, and Healthy Control Subjects. *JACC: Cardiovascular*
- 453 *Imaging* (2018) 11:577–85. doi: 10.1016/j.jcmg.2017.05.022
- 454 28. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P,
- 455 Castiello T, Wong K, Zhang J, Cleland JGF, Clark AL. Global longitudinal strain
- 456 in patients with suspected heart failure and a normal ejection fraction: does it
- 457 improve diagnosis and risk stratification? *The International Journal of*
- 458 *Cardiovascular Imaging* (2013) 30:69–79. doi: 10.1007/s10554-013-0310-y
- 459 29. Roy C, Lejeune S, Slimani A, Meester C, Ahn AS SA, Rousseau MF, Mihaela A,
- 460 Ginion A, Ferracin B, Pasquet A, et al. Fibroblast growth factor 23: a biomarker
- 461 of fibrosis and prognosis in heart failure with preserved ejection fraction. *ESC*
- 462 *Heart Failure* (2020) 7:2494–507. doi: 10.1002/ehf2.12816
- 463 30. Sanchis L, Gabrielli L, Andrea R, Falces C, Duchateau N, Perez-Villa F, Bijmens
- 464 B, Sitges M. Left atrial dysfunction relates to symptom onset in patients with
- 465 heart failure and preserved left ventricular ejection fraction. *European Heart*
- 466 *Journal - Cardiovascular Imaging* (2015) 16:62–7. doi: 10.1093/ehjci/jeu165
- 467 31. Stoichescu-Hogea G, Buleu FN, Christodorescu R, Sosdean R, Tudor A, Ember
- 468 A, Brie DM, Drăgan S. Contribution of Global and Regional Longitudinal Strain
- 469 for Clinical Assessment of HFpEF in Coronary and Hypertensive Patients.
- 470 *Medicina* (2021) 57:1372. doi: 10.3390/medicina57121372
- 471 32. Tanacli R, Hashemi D, Neye M, Motzkus LA, Blum M, Tahirovic E, Dordevic
- 472 A, Kraft R, Zamani SM, Pieske B, et al. Multilayer myocardial strain improves
- 473 the diagnosis of heart failure with preserved ejection fraction. *ESC Heart Failure*
- 474 (2020) 7:3240–5. doi: 10.1002/ehf2.12826
- 475 33. Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left
- 476 ventricular twist and circumferential deformation, but depressed longitudinal and
- 477 radial deformation in patients with diastolic heart failure. *European Heart*

- 478 *Journal* (2008) 29:1283–9. doi: 10.1093/eurheartj/ehn141
- 479 34. Yip GW-K., Zhang Q, Xie J-M., Liang Y-J., Liu Y-M., Yan B, Lam Y-Y., Yu
- 480 C-M. Resting global and regional left ventricular contractility in patients with
- 481 heart failure and normal ejection fraction: insights from speckle-tracking
- 482 echocardiography. *Heart* (2011) 97:287–94. doi: 10.1136/hrt.2010.205815
- 483 35. Maffei C, Rossi A, Cannata L, Zocco C, Belyavskiy E, Radhakrishnan AK,
- 484 Feuerstein A, Morris DA, Pieske-Kraigher E, Pieske B, et al. Left atrial strain
- 485 predicts exercise capacity in heart failure independently of left ventricular
- 486 ejection fraction. *ESC Heart Failure* (2022) 9:842–52. doi: 10.1002/ehf2.13788
- 487 36. Michalski B, Trzeciński P, Kupczyńska K, Miśkowiec D, Pęczek Ł, Nawrot B,
- 488 Lipiec P, Kasprzak JD. The differences in the relationship between diastolic
- 489 dysfunction, selected biomarkers and collagen turn-over in heart failure patients
- 490 with preserved and reduced ejection fraction. *Cardiology Journal* (2017) 24:35–
- 491 42. doi: 10.5603/cj.a2016.0098
- 492 37. Obokata M, Takeuchi M, Negishi K, Ohte N, Izumo M, Yamashita E, Ebato M,
- 493 Yuda S, Kurabayashi M, Nakatani S. Relation Between Echocardiogram-Based
- 494 Cardiac Parameters and Outcome in Heart Failure With Preserved and Reduced
- 495 Ejection Fraction. *The American Journal of Cardiology* (2016) 118:1356–62. doi:
- 496 10.1016/j.amjcard.2016.07.060
- 497 38. Park JJ, Park J-B, Park J-H, Cho G-Y. Global Longitudinal Strain to Predict
- 498 Mortality in Patients With Acute Heart Failure. *Journal of the American College*
- 499 *of Cardiology* (2018) 71:1947–57. doi: 10.1016/j.jacc.2018.02.064
- 500 39. Tanacli R, Hashemi D, Lapinskas T, Edelmann F, Gebker R, Pedrizzetti G,
- 501 Schuster A, Nagel E, Pieske B, Dünge H-D, et al. Range Variability in CMR
- 502 Feature Tracking Multilayer Strain across Different Stages of Heart Failure.
- 503 *Scientific Reports* (2019) 9:16478. doi: 10.1038/s41598-019-52683-8
- 504 40. Xu L, Pagano J, Chow K, Oudit GY, Haykowsky MJ, Mikami Y, Howarth AG,
- 505 White JA, Howlett JG, Dyck JRB, et al. Cardiac remodelling predicts outcome in
- 506 patients with chronic heart failure. *ESC Heart Failure* (2021) 8:5352–62. doi:
- 507 10.1002/ehf2.13626
- 508 41. Gozdzik A, Marwick TH, Przewlocka-Kosmala M, Jankowska EA, Ponikowski
- 509 P, Kosmala W. Comparison of left ventricular longitudinal systolic function
- 510 parameters in the prediction of adverse outcome in heart failure with preserved
- 511 ejection fraction. *ESC Heart Failure* (2021) 8:1531–40. doi: 10.1002/ehf2.13247
- 512 42. Kalra R, Gupta K, Sheets R, Aryal S, Ebrahimi A, Rajapreyar I, Cribbs MG,
- 513 Booker OJ, Prabhu SD, Bajaj NS. Cardiac Function and Sudden Cardiac Death in
- 514 Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). *The*
- 515 *American Journal of Cardiology* (2020) 129:46–52. doi:
- 516 10.1016/j.amjcard.2020.04.038
- 517 43. Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Schönbauer R, Duca
- 518 F, Zotter-Tufaro C, Binder C, Aschauer S, Beitzke D, et al. Feature Tracking of
- 519 Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk
- 520 Stratification in Heart Failure with Preserved Ejection Fraction. *Radiology* (2020)
- 521 296:290–8. doi: 10.1148/radiol.2020200195
- 522 44. Romano S, Judd RM, Kim RJ, Heitner JF, Shah DJ, Shenoy C, Evans K, Romer
- 523 B, Salazar P, Farzaneh-Far A. Feature-Tracking Global Longitudinal Strain

- 524 Predicts Mortality in Patients With Preserved Ejection Fraction. *JACC:*  
525 *Cardiovascular Imaging* (2020) 13:940–7. doi: 10.1016/j.jcmg.2019.10.004
- 526 45. Hwang I-C, Cho G-Y, Choi H-M, Yoon YE, Park JJ, Park J-B, Park J-H, Lee S-  
527 P, Kim H-K, Kim Y-J. H2FPEF Score Reflects the Left Atrial Strain and Predicts  
528 Prognosis in Patients With Heart Failure With Preserved Ejection Fraction.  
529 *Journal of Cardiac Failure* (2021) 27:198–207. doi:  
530 10.1016/j.cardfail.2020.09.474
- 531 46. Donal E, Lund LH, Oger E, Bosseu C, Reynaud A, Hage C, Drouet E, Daubert  
532 J-Claude, Linde C. Importance of combined left atrial size and estimated  
533 pulmonary pressure for clinical outcome in patients presenting with heart failure  
534 with preserved ejection fraction. *European Heart Journal - Cardiovascular*  
535 *Imaging* (2017) 18:629–35. doi: 10.1093/ehjci/jex005
- 536 47. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ,  
537 Velazquez EJ. Left ventricular global longitudinal strain in patients with heart  
538 failure with preserved ejection fraction: outcomes following an acute heart failure  
539 hospitalization. *ESC Heart Failure* (2017) 4:432–9. doi: 10.1002/ehf2.12159
- 540 48. Wang J, Fang F, Wai-Kwok Yip G, Sanderson JE, Feng W, Xie J-M, Luo X-X,  
541 Lee AP-W, Lam Y-Y. Left ventricular long-axis performance during exercise is  
542 an important prognosticator in patients with heart failure and preserved ejection  
543 fraction. *International Journal of Cardiology* (2015) 178:131–5. doi:  
544 10.1016/j.ijcard.2014.10.130
- 545 49. Huang W, Chai SC, Lee SGS, MacDonald MR, Leong KTG. Prognostic Factors  
546 After Index Hospitalization for Heart Failure With Preserved Ejection Fraction.  
547 *The American Journal of Cardiology* (2017) 119:2017–20. doi:  
548 10.1016/j.amjcard.2017.03.032
- 549 50. Freed BH, Daruwalla V, Cheng JY, Aguilar FG, Beussink L, Choi A, Klein DA,  
550 Dixon D, Baldrige A, Rasmussen-Torvik LJ, et al. Prognostic Utility and  
551 Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved  
552 Ejection Fraction. *Circulation: Cardiovascular Imaging* (2016) 9:e003754. doi:  
553 10.1161/circimaging.115.003754
- 554 51. Lejeune S, Roy C, Ciocea V, Slimani A, de Meester C, Amzulescu M, Pasquet A,  
555 Vancraeynest D, Beauloye C, Vanoverschelde J-L, et al. Right Ventricular  
556 Global Longitudinal Strain and Outcomes in Heart Failure with Preserved  
557 Ejection Fraction. *Journal of the American Society of Echocardiography* (2020)  
558 33:973-984.e2. doi: 10.1016/j.echo.2020.02.016
- 559 52. Weerts J, Barandiarán Aizpurua A, Henkens MTHM, Lyon A, van Mourik MJW,  
560 van Gemert MRAA, Raafs A, Sanders-van Wijk S, Bayés-Genís A, Heymans  
561 SRB, et al. The prognostic impact of mechanical atrial dysfunction and atrial  
562 fibrillation in heart failure with preserved ejection fraction. *European Heart*  
563 *Journal - Cardiovascular Imaging* (2021) 23:74–84. doi: 10.1093/ehjci/jeab222
- 564 53. Kosmala W, Przewlocka-Kosmala M, Rojek A, Mysiak A, Dabrowski A,  
565 Marwick TH. Association of Abnormal Left Ventricular Functional Reserve  
566 With Outcome in Heart Failure With Preserved Ejection Fraction. *JACC:*  
567 *Cardiovascular Imaging* (2018) 11:1737–46. doi: 10.1016/j.jcmg.2017.07.028
- 568 54. Pieske B, Tschöpe C, Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu  
569 M, Guazzi M, Lam CSP, et al. How to diagnose heart failure with preserved



- 570 ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus  
571 recommendation from the Heart Failure Association (HFA) of the European  
572 Society of Cardiology (ESC). *European Journal of Heart Failure* (2020) 22:391–  
573 412. doi: 10.1002/ejhf.1741
- 574 55. Buckberg G, Hoffman JIE, Mahajan A, Saleh S, Coghlan C. Cardiac Mechanics  
575 Revisited. *Circulation* (2008) 118:2571–87. doi:  
576 10.1161/circulationaha.107.754424
- 577 56. Moslehi JJ, Witteles RM. Global Longitudinal Strain in Cardio-Oncology.  
578 *Journal of the American College of Cardiology* (2021) 77:402–4. doi:  
579 10.1016/j.jacc.2020.12.014
- 580 57. Sivapathan S, Geenty P, Deshmukh T, Boyd A, Richards D, Stewart G, Taylor  
581 MS, Kwok F, Thomas L. Alterations in multi-layer strain in AL amyloidosis.  
582 *Amyloid* (2022) 21:1–9. doi: 10.1080/13506129.2022.2026914
- 583 58. Steen H, Giusca S, Montenbruck M, Patel AR, Pieske B, Florian A, Erley J,  
584 Kelle S, Korosoglou G. Left and right ventricular strain using fast strain-encoded  
585 cardiovascular magnetic resonance for the diagnostic classification of patients  
586 with chronic non-ischemic heart failure due to dilated, hypertrophic  
587 cardiomyopathy or cardiac amyloidosis. *Journal of Cardiovascular Magnetic  
588 Resonance* (2021) 23:45. doi: 10.1186/s12968-021-00711-w
- 589 59. Hiemstra YL, Tomsic A, van Wijngaarden SE, Palmen M, Klautz RJM, Bax JJ,  
590 Delgado V, Ajmone Marsan N. Prognostic Value of Global Longitudinal Strain  
591 and Etiology After Surgery for Primary Mitral Regurgitation. *JACC:  
592 Cardiovascular Imaging* (2020) 13:577–85. doi: 10.1016/j.jcmg.2019.03.024
- 593 60. Shehata ML, Harouni AA, Skrok J, Basha TA, Boyce D, Lechtzin N, Mathai SC,  
594 Girgis R, Osman NF, Lima JAC, et al. Regional and Global Biventricular  
595 Function in Pulmonary Arterial Hypertension: A Cardiac MR Imaging Study.  
596 *Radiology* (2013) 266:114–22. doi: 10.1148/radiol.12111599
- 597 61. Fan L, Namani R, Choy JS, Kassab GS, Lee LC. Transmural Distribution of  
598 Coronary Perfusion and Myocardial Work Density Due to Alterations in  
599 Ventricular Loading, *Geometry and Contractility*. *Frontiers in Physiology* (2021)  
600 12:744855. doi: 10.3389/fphys.2021.744855
- 601 62. Xu L, Pagano JJ, Haykowsky MJ, Ezekowitz JA, Oudit GY, Mikami Y, Howarth  
602 A, White JA, Dyck JRB, Anderson T, et al. Layer-specific strain in patients with  
603 heart failure using cardiovascular magnetic resonance: not all layers are the same.  
604 *Journal of Cardiovascular Magnetic Resonance* (2020) 22:81. doi:  
605 10.1186/s12968-020-00680-6
- 606 63. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A,  
607 Khan JN, Chan DCS, Squire IB, Ng LL, et al. Prevalence and Prognostic  
608 Significance of Microvascular Dysfunction in Heart Failure With Preserved  
609 Ejection Fraction. *JACC: Cardiovascular Imaging* (2022) 5:S1936-  
610 878X(21)008937. doi: 10.1016/j.jcmg.2021.11.022
- 611  
612  
613  
614  
615

616 **Tabel 1. Baseline characteristics of the 41 selected research**

617

| NO | Study                | Country     | Sample size , n | HFpEF patients, n | Males , n | Age, mean (SD), years | Study design | LV GLS detection method | Mean or median values of LV GLS in HFpEF patients (%) | Endpoint (s) | NOS quality score |
|----|----------------------|-------------|-----------------|-------------------|-----------|-----------------------|--------------|-------------------------|-------------------------------------------------------|--------------|-------------------|
| 1  | Ito2020              | Japan       | 36              | 18                | 10        | 63                    | Case-control | FT-CMR                  | -14.8±3.3                                             | A            | 8                 |
| 2  | Mordi2018            | Uk          | 90              | 62                | 34        | 69.3                  | Case-control | STE                     | -16.0±2.2                                             | A, C         | 7                 |
| 3  | Stoichescu-Hogea2018 | Romania     | 102             | 62                | 53        | 61.5                  | Case-control | STE                     | -17.6±2.3                                             | A, C         | 8                 |
| 4  | Carluccio2016        | Italy       | 86              | 46                | 38        | 70                    | Case-control | STE                     | -15.4±3.5                                             | A            | 8                 |
| 5  | Löffler2019          | US          | 34              | 19                | 17        | 61                    | Case-control | FT-CMR                  | -17.9±3.5                                             | A            | 7                 |
| 6  | Maffeis2022          | Germany     | 171             | 86                | 136       | 65                    | Case-control | STE                     | -19.0 ± 3.0                                           | B            | 6                 |
| 7  | Hashemi2021          | Germany     | 49              | 19                | 35        | 66.9                  | Case-control | FT-CMR                  | -19.2±1.3                                             | A, B         | 8                 |
| 8  | Bekfani2021          | US          | 55              | 17                | 30        | 68.3                  | Case-control | STE                     | -18.9 ± 5.5                                           | A, B         | 7                 |
| 9  | Blum2020             | Germany     | 54              | 17                | 34        | 68.3                  | Case-control | FT-CMR                  | -19.1±1.2                                             | A, B         | 8                 |
| 10 | Park2018             | South Korea | 3530            | 1335              | 1848      | 70.8                  | Case-control | STE                     | -15.2±4.6                                             | B            | 9                 |
| 11 | Sanchis2015          | Spain       | 138             | 63                | 90        | 75                    | Case-control | STE                     | -16.0 + 3.7                                           | A, B         | 7                 |
| 12 | Bosch2017            | Netherlands | 657             | 219               | 328       | 66                    | Case-control | STE                     | -14.5±4.0                                             | A, B         | 7                 |
| 13 | Bshiebish2019        | Iraq        | 66              | 20                | 38        | 59                    | Case-control | STE                     | -15.0±2.0                                             | A, B         | 8                 |
| 14 | Michalski2017        | Poland      | 62              | 32                | 32        | 62.3                  | Case-control | STE                     | -16.1±6.4                                             | B            | 8                 |
| 15 | Luo2014              | China       | 149             | 45                | 93        | 61                    | Case-control | STE                     | -14.0±2.7                                             | A, B         | 7                 |
| 16 | Fang2019             | China       | 112             | 62                | 61        | 67.5                  | Case-control | STE                     | -14.5±2.6                                             | A, C         | 7                 |
| 17 | Tanacli2020          | Germany     | 40              | 20                | 24        | 70.8                  | Case-control | FT-CMR                  | -20.8±4.0                                             | A, C         | 8                 |
| 18 | Kim2020              | South Korea | 96              | 50                | 42        | 62.8                  | Case-control | STE                     | -15.5±5.3                                             | A, C         | 8                 |
| 19 | Kraigher-Krainer2014 | Austria     | 269             | 219               | 140       | 70                    | Case-control | STE                     | -14.6 ±3.3                                            | A            | 7                 |
| 20 | Tanacli2019          | Germany     | 55              | 18                | 30        | 66.7                  | Case-control | FT-CMR                  | -12.2 ± 2.1                                           | B            | 7                 |
| 21 | Yip2011              | China       | 347             | 112               | 158       | 64.7                  | Case-control | STE                     | -15.9 ±3.9                                            | A, B         | 8                 |
| 22 | Wang2008             | US          | 67              | 20                | 42        | 52.3                  | Case-control | STE                     | -13.0 ±6.0                                            | A, B, C      | 7                 |
| 23 | Carluccio2011        | Netherlands | 137             | 47                | 78        | 62.7                  | Case-control | STE                     | -14.4±3.3                                             | A, B         | 7                 |
| 24 | Pellicori2014        | UK          | 158             | 138               | 96        | 71.5                  | Case-control | STE                     | -13.6±3.0                                             | A, D         | 6                 |

618

619 **Continued Tabel 1. Baseline characteristics of the 41 selected research**

| NO | Study            | Country     | Sample size , n | HFpEF patients, n | Males , n | Age, mean (SD), years | Study design         | LV GLS detection method | Mean or median values of LV GLS in HFpEF patients (%) | Endpoint(s) | NOS quality score |
|----|------------------|-------------|-----------------|-------------------|-----------|-----------------------|----------------------|-------------------------|-------------------------------------------------------|-------------|-------------------|
| 25 | Xu2021           | Canada      | 262             | 97                | 100       | 69                    | Case-control         | FT-CMR:                 | -18.0±3.0                                             | B, D        | 8                 |
| 26 | Roy2020          | Brussels    | 174             | 143               | 56        | 73                    | Case-control         | STE                     | -16.5±3.2                                             | A, D        | 7                 |
| 27 | Obokata2016      | Japan       | 442             | 102               | 265       | 74                    | Case-control         | STE                     | 14.3±2.8                                              | B, D        | 6                 |
| 28 | Gozdzik2021      | Australia   | 201             | 201               | 53        | 64.8                  | Prospective cohort   | STE                     | 18.3±3.2                                              | D           | 7                 |
| 29 | Kalra2020        | US          | 1767            | 1767              | 885       | 72                    | Retrospective cohort | STE                     | -15.6                                                 | D           | 8                 |
| 30 | Kammerlander2020 | Austria     | 206             | 206               | 63        | 71                    | Prospective cohort   | FT-CMR                  | -8.2±4.5                                              | D           | 8                 |
| 31 | Romano2020       | US          | 1274            | 1274              | 681       | 57.1                  | Retrospective cohort | FT-CMR                  | -20                                                   | D           | 8                 |
| 32 | Hwang2021        | South Korea | 1105            | 1105              | 435       | 77                    | Prospective cohort   | STE                     | -15.3                                                 | D           | 9                 |
| 33 | Donal2017        | France      | 237             | 237               | 102       | 76                    | Prospective cohort   | STE                     | -14.9±3.71                                            | D           | 7                 |
| 34 | Buggey2017       | US          | 739             | 739               | 177       | 69                    | Prospective cohort   | STE                     | -13.4±3.8                                             | D           | 8                 |
| 35 | Wang2015         | China       | 80              | 80                | 50        | 66                    | Prospective cohort   | STE                     | -18.15±3.3                                            | D           | 8                 |
| 36 | Huang2017        | Singapore   | 129             | 129               | 67        | 75.1                  | Prospective cohort   | STE                     | -13.5±4.0                                             | D           | 7                 |
| 37 | Shah2015         | US          | 447             | 447               | 207       | 70.3                  | Prospective cohort   | STE                     | -15.6±3.5                                             | D           | 9                 |
| 38 | Freed2016        | Chicago     | 308             | 308               | 111       | 65                    | Prospective cohort   | STE                     | -17.5±4.1                                             | D           | 8                 |
| 39 | Lejeune2020      | Belgium     | 149             | 149               | 58        | 78                    | Prospective cohort   | STE                     | -16.7±3.1                                             | D           | 7                 |
| 40 | Weerts2021       | Spain       | 258             | 258               | 79        | 75.6                  | Prospective cohort   | STE                     | -17.7±4.4                                             | D           | 6                 |
| 41 | Kosmala2018      | Australia   | 205             | 205               | 55        | 64.8                  | Prospective cohort   | STE                     | -18.2±3.4                                             | D           | 8                 |

620 **Abbreviations:** HFpEF: Heart (HF) with preserved ejection fraction; STE: speckle-tracking echocardiography; FT-CMR: feature-tracking cardiovascular magnetic  
621 resonance

622 **Endpoint (s) :** A: Differences in LV GLS Values between HFpEF Patients and Healthy Controls; B: Differences in LV GLS Values between HFpEF Patients and HFrEF  
623 Patients; C: Diagnostic Value of LV GLS Values in HFpEF; D: Prognostic Value of LV GLS Values in HFpEF Patients

624

625

626

627 **Table 2. Data related to diagnostic meta-analysis**

|   | <b>Study</b>         | <b>LVGLS cut-off (%)</b> | <b>AUC</b> | <b>SEN (%)</b> | <b>SPE(%)</b> | <b>TP</b> | <b>FP</b> | <b>FN</b> | <b>TN</b> | <b>P-value</b> |
|---|----------------------|--------------------------|------------|----------------|---------------|-----------|-----------|-----------|-----------|----------------|
| 1 | Mordi2018            | -17.8                    | 0.78       | 0.83           | 0.63          | 52        | 10        | 11        | 17        | 0.037          |
| 2 | Stoichescu-Hogea2018 | -19.35                   | 0.83       | 0.79           | 0.47          | 49        | 21        | 13        | 19        | <0.001         |
| 3 | Fang2019             | —                        | 0.87       | —              | —             | —         | —         | —         | —         | <0.001         |
| 4 | Tanacli2020          | -24.1                    | 0.69       | 0.90           | 0.41          | 18        | 12        | 2         | 8         | 0.037          |
| 5 | Kim2020              | -16.7                    | 0.68       | 0.54           | 0.85          | 27        | 7         | 23        | 39        | 0.001          |
| 6 | Wang2008             | -16                      | 0.98       | 0.95           | 0.95          | 19        | 1         | 1         | 16        | <0.001         |

628 **Abbreviations:** LV GLS: left ventricular global longitudinal strain **TP:** True positive; **FP:** False positive; **FN:** False negative; **TN:** True negative; **SEN:** Sensitivity;  
629 **SPE:** Specificity.

630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646



647 **Table 3. Data related to Meta-analysis of prognostic assessment**

| NO | Study            | Variables adjusted                                                                                                                                                                                                    | Follow-up Duration (months) | Endpoint(s)                            | Hazard ratios | 95% CIs     | P-value |
|----|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------------|---------------|-------------|---------|
| 1  | Pellicori2014    | –                                                                                                                                                                                                                     | 21.6                        | CV death and HF hospitalization        | 1.09          | 1.00–1.19   | 0.046   |
| 2  | Xu2021           | –                                                                                                                                                                                                                     | 90                          | All-cause death and CV hospitalization | 1.00          | 0.98-1.02   | 0.93    |
| 3  | Roy2020          | –                                                                                                                                                                                                                     | 30                          | All cause death                        | 1.04          | 0.94-1.15   |         |
| 4  | Obokata2016      | –                                                                                                                                                                                                                     | 11.4                        | All-cause death and HF hospitalization | 1.00          | 0.93-1.07   | 0.95    |
| 5  | Obokata2016      | –                                                                                                                                                                                                                     | 11.4                        | CV death and HF hospitalization        | 0.99          | 0.87-1.13   | 0.92    |
| 5  | Gozdzik2021      | MAGGIC Risk Score, BNP, and peak VO2                                                                                                                                                                                  | 48                          | CV death and HF hospitalization        | 0.91          | 0.84-0.98   | 0.016   |
| 6  | Kalra2020        | Age, sex, race, medical history (stroke, heart rate, and AF), NYHA class, randomization strata, randomized treatment assignment, hematocrit, and creatinine.                                                          | 34.8                        | All-cause death                        | 1.58          | 1.12-2.22   | 0.009   |
| 7  | Kammerlander2020 | Age, sex, NT-pro BNP, LA volume, RV end-diastolic volume, and RV ejection fraction                                                                                                                                    | 39                          | CV death and HF hospitalization        | 1.06          | 1.01- 1.11  | 0.03    |
| 8  | Romano2020       | Age, BMI, medical history (diabetes, hypertension), heart rate, diastolic blood pressure, LV end diastolic volume index, LV ejection fraction, LA volume, and RV ejection fraction                                    | 74.4                        | All case death                         | 1.21          | 1.157–1.270 | <0.001  |
| 9  | Hwang2021        | –                                                                                                                                                                                                                     | 30                          | All-cause death and HF hospitalization | 1.40          | 1.176–1.667 | <0.001  |
| 10 | Donal2017        | Age, sex, medical history (arterial hypertension, AF, and renal insufficiency ) , and hemoglobin.                                                                                                                     | 18                          | All-cause death and HF hospitalization | 1.94          | 1.22 3.07   | 0.0047  |
| 11 | Buggey2017       | Age, sex, medical history (renal insufficiency, diabetes, hypertension, lung disease), systolic blood pressure, NT-pro BNP, RV systolic pressure, moderate mitral stenosis, moderate aortic stenosis, and E/e' ratio. | 12                          | All case death                         | 1.02          | 0.96–1.08   | 0.562   |
| 12 | Wang2015         | Age, sex, medical history (hypertension, diabetes mellitus, and anemia), history of cardiac-related medications, the body surface area, NYHA class                                                                    | 36                          | All-cause death and HF hospitalization | 1.03          | 0.98–1.08   | 0.204   |
| 13 | Huang2017        | Sex, race, BMI, echocardiography data, NT-pro BNP, and Troponin T.                                                                                                                                                    | 37.5                        | All-cause death                        | 0.79          | 0.67–0.91   | 0.008   |
| 14 | Shah2015         | Age, sex, race, medical history (AF, stroke), heart rate, NYHA class, creatinine, echocardiography data (LVEF, LV mass, E/e' ratio.), randomization strata, region of enrollment, randomized treatment assignment     | 34.8                        | All-cause death                        | 4.72          | 1.25-17.81  | 0.022   |
|    |                  |                                                                                                                                                                                                                       |                             | CV death and HF hospitalization        | 2.14          | 1.26-3.66   | 0.005   |

648

649 **Continued Tabel 3. Data related to Meta-analysis of prognostic assessment**

| NO | Study       | Variables adjusted                                         | Follow-up Duration (months) | Endpoint(s)                            | Hazard ratios | 95% CIs     | P-value |
|----|-------------|------------------------------------------------------------|-----------------------------|----------------------------------------|---------------|-------------|---------|
| 15 | Freed2016   | Sex, AF, MAGGIC Risk Score, LV mass, LA volume, E/e' ratio | 13.8                        | All-cause death and CV hospitalization | 1.17          | 0.95–1.43   | 0.13    |
| 16 | Lejeune2020 | –                                                          | 30                          | All-cause death and HF hospitalization | 1.066         | 0.964–1.178 | 0.22    |
| 17 | Weerts2021  | –                                                          | 36                          | All-cause death and HF hospitalization | 1.019         | 0.951–1.093 | 0.59    |
| 18 | Kosmala2018 | –                                                          | 26.2                        | HF Hospitalization                     | 0.958         | 0.909–1.010 | 0.115   |
|    |             |                                                            |                             | All-cause death and CV hospitalization | 1.76          | 0.23–13.52  | 0.584   |
|    |             |                                                            |                             |                                        | 2.12          | 0.35–12.74  | 0.411   |

650 **Abbreviations: MAGGIC Risk Score:** age, ejection fraction, creatinine, diabetes, chronic obstructive pulmonary disease, systolic blood pressure, body-mass index, heart  
651 rate, New York Heart Association functional class, ACE-inhibitor use, beta-blocker use, heart failure duration, and current smoker; **AF:** atrial fibrillation; **NYHA:** New  
652 York Heart Association; **LA:** left atrial volume; **RV:** right ventricular; **LV:** left ventricular; **BMI:** body-mass index; **LVEF:** LV ejection fraction.

653

654

655

656

657

658

659

660

661

## 662 **Figure Legends**

663 **Fig.1** Flowchart of Database Search and Text Screening Procedure

664 **Fig.2** Differences in LV GLS Values between HFpEF Patients and Control Groups

665 (A) Mean LV GLS Values in HFpEF Patients and Healthy Controls

666 (B) Mean LV GLS Values in HFpEF Patients and HFrEF Patients

667 (C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls

668 (D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients

669 **Fig.3** Diagnostic Value of LVGLS in Patients with HFpEF

670 (A) Sensitivity

671 (B) Specificity

672 (C) Positive Likelihood Ratio

673 (D) Negative Likelihood Ratio

674 (E) Diagnostic Odds Ratio

675 (F) SROC

676 **Fig.4** Associations between Low LV GLS Values and Adverse Outcomes in HFpEF Patients

677 (A) Forest Plot of the Association between Low LV GLS Values and All-cause Death in  
678 HFpEF Patients

679 (B) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome  
680 of All-cause Death and HF Hospitalization in HFpEF Patients

681 (C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome  
682 of CV Death and HF Hospitalization in HFpEF Patients






Fig.1 Flowchart of Database Search and Text Screening Procedure

(A) Mean LV GLS Values in HFpEF Patients and Healthy Controls (B) Mean LV GLS Values in HFpEF Patients and HFrEF Patients



(C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls



(D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients





Fig.2 Differences in LV GLS Values between HFpEF Patients and




### (A) Sensitivity



| Study                | Sensitivity (95% CI) |
|----------------------|----------------------|
| Mordi2018            | 0.83 (0.71 - 0.91)   |
| Stoichescu-Hogea2018 | 0.88 (0.81 - 0.95)   |
| Tanacli2020          | 0.85 (0.78 - 0.92)   |
| Kim2020              | 0.54 (0.39 - 0.68)   |
| Wang2008             | 0.95 (0.75 - 1.00)   |

Pooled Sensitivity = 0.77 (0.71 to 0.82)  
Chi-square = 21.24; df = 4 (p = 0.0003)  
Inconsistency (I-square) = 81.2 %


### (B) Specificity



| Study                | Specificity (95% CI) |
|----------------------|----------------------|
| Mordi2018            | 0.63 (0.42 - 0.81)   |
| Stoichescu-Hogea2018 | 0.47 (0.32 - 0.64)   |
| Tanacli2020          | 0.41 (0.19 - 0.64)   |
| Kim2020              | 0.85 (0.71 - 0.94)   |
| Wang2008             | 0.95 (0.71 - 1.00)   |

Pooled Specificity = 0.66 (0.58 to 0.74)  
Chi-square = 27.60; df = 4 (p = 0.0000)  
Inconsistency (I-square) = 85.5 %


### (C) Positive Likelihood Ratio



| Study                | Positive LR (95% CI)  |
|----------------------|-----------------------|
| Mordi2018            | 2.23 (1.35 - 3.69)    |
| Stoichescu-Hogea2018 | 1.51 (1.09 - 2.08)    |
| Tanacli2020          | 1.50 (1.02 - 2.21)    |
| Kim2020              | 3.55 (1.71 - 7.35)    |
| Wang2008             | 16.15 (2.41 - 108.42) |

Random Effects Model  
Pooled Positive LR = 2.17 (1.36 to 3.47)  
Cochran-Q = 14.77; df = 4 (p = 0.0052)  
Inconsistency (I-square) = 72.9 %  
Tau-squared = 0.1815


### (D) Negative Likelihood Ratio



| Study                | Negative LR (95% CI) |
|----------------------|----------------------|
| Mordi2018            | 0.28 (0.15 - 0.51)   |
| Stoichescu-Hogea2018 | 0.44 (0.25 - 0.79)   |
| Tanacli2020          | 0.25 (0.06 - 1.03)   |
| Kim2020              | 0.54 (0.39 - 0.75)   |
| Wang2008             | 0.05 (0.01 - 0.36)   |

Random Effects Model  
Pooled Negative LR = 0.35 (0.21 to 0.59)  
Cochran-Q = 10.80; df = 4 (p = 0.0289)  
Inconsistency (I-square) = 63.0 %  
Tau-squared = 0.1922

### (E) Diagnostic Odds Ratio



| Study                | Diagnostic OR(95% CI)     |
|----------------------|---------------------------|
| Mordi2018            | 8.04 (2.91 - 22.21)       |
| Stoichescu-Hogea2018 | 3.41 (1.43 - 8.15)        |
| Tanacli2020          | 6.00 (1.08 - 33.27)       |
| Kim2020              | 6.54 (2.46 - 17.39)       |
| Wang2008             | 304.00 (17.58 - 5,258.01) |

Random Effects Model


Pooled Diagnostic Odds Ratio = 7.53 (3.19 to 17.74)

Cochran-Q=9.34;df=4(p=0.0531)

Inconsistency(I-square)=57.2%

Tau-squared=0.5023


### (F) SROC




Symmetric SROC  
AUC=0.81 (0.79-0.87)  
SE(AUC)=0.0588  
Q=0.7488  
SE(Q)=0.0524

Fig.3 Diagnostic Value of LVGLS in Patients with HFpEF

(A) Forest Plot of the Association between Low LV GLS Values and All-cause Death in HFpEF Patients



(B) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome of All-cause Death and HF Hospitalization in HFpEF Patients



(C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome of CV Death and HF Hospitalization in HFpEF Patients




Fig.4 Associations between Low LV GLS Values and Adverse Outcomes